Tag: Kurzweil Scorecard
-
Kurzweil predicted in 2005 that stem-cell restrictions would accelerate transdifferentiation. A year later, Yamanaka did exactly that. Here is what the rest of his regulation thesis got right — and what 2025 is quietly rewriting.
-
Kurzweil in 2005 picked torcetrapib and Apo-A-I Milano as his evidence that atherosclerosis reversal was imminent. Both failed. The drugs that actually regressed plaque came from mechanisms his book did not name.
-
One vindication by procurement, one falsification by Eroom’s Law, and a nanobot deadline that even Kurzweil has pushed back.
-
Every mechanism Kurzweil predicted for 2010s nanomedicine has now worked in a human body at least once. The clinic still looks nothing like he drew.
-
Seven 2005 predictions about replacement organs, therapeutic cloning, and bloodstream nanobots — graded against 2026 reality.
-
Kurzweil’s press-a-button cancer kill arrived — just not through the mechanism he predicted. Respirocytes and microbivores remain on paper.
-
Ten things Kurzweil said were already true in 2005, audited against 2026 evidence. The most-cited stat about the human body turns out to be wrong — in both directions.
-
Twenty-one years after Singularity Is Near, ten claims Kurzweil said were already true: what held up, what got overtaken, and the company whose path he rewrote.
-
The endocrine organ MicroCHIPS was supposed to ship by 2008 now rides a belt clip — while a May 2024 patent claims Kurzweil’s telomere-reset stem cells nearly word-for-word.
-
Kurzweil called the targets on medicine but missed the projectiles: wastewater not serum, mRNA not RNAi, senolytics not nanobots.